Et prospektivt observationsstudie af tidlig debuterende mave-tarmkræft: Fra tumorpræg til patienters livsstilsvaner (YOGICO)
Et prospektivt observationsstudie af tidligopstået mave-tarmkræft: Fra tumorfunktioner til patienters livsstilsvaner - YOGICO-studiet
The YOGICO study aims to characterize the distinctive features of EoGI cancer through a holistic approach that integrates clinical and demographic data, tumor biological characteristics, and patient lifestyle habits
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This is an observational, prospective multicenter study to characterize newly diagnosed EoGI cancer patients from a holistic approach, covering aspects from tumor features to patient lifestyle habits. Since this is a prospective observational study, participation does not alter any cancer treatments that patients will undergo after their cancer diagnosis, as per best clinical practice at each participating center. The number of patients included in the study will range from 150 to 200, enrolled in national centers located in northern Italy, as well as in diverse hospital settings (e.g., small vs. large hospitals).
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Ilaria Bernardini, MD
- Telefonnummer: +39 059659294
- E-mail: i.bernardini@ausl.mo.it
Studiesteder
-
-
BO
-
Bologna, BO, Italien
- Ikke rekrutterer endnu
- Oncologia, Ospedale Sant'Orsola
-
Kontakt:
- Karim Rihawi, MD
-
-
FC
-
Meldola, FC, Italien
- Aktiv, ikke rekrutterende
- Istituto Romagnolo per lo studio dei tumori "Dino Amadori", IRCCS IRST
-
-
MO
-
Carpi, MO, Italien
- Rekruttering
- Oncologia di Prossimità, Ospedale di Carpi e DHO Mirandola, Ausl Modena
-
Kontakt:
- Claudia Mucciarini, MD
-
Modena, MO, Italien
- Aktiv, ikke rekrutterende
- Centro Oncologico Modenese, Azienda Policlinico Universitaria di Modena
-
Sassuolo, MO, Italien
- Rekruttering
- Oncologia Area Sud Ausl Modena
-
Kontakt:
- Teresa Zielli, MD
-
-
Minnesota
-
Mantua, Minnesota, Italien
- Aktiv, ikke rekrutterende
- Oncologia Ospedale Carlo Poma di Mantova
-
-
PC
-
Piacenza, PC, Italien
- Aktiv, ikke rekrutterende
- Oncologia Medica, AUSL Piacenza
-
-
PR
-
Parma, PR, Italien
- Rekruttering
- Oncologia, Azienda Ospedaliero Universitaria di Parma
-
Kontakt:
- Annalisa Gilli, MD
-
-
RE
-
Reggio Emilia, RE, Italien
- Rekruttering
- Oncologia Medica, CORE Azienda USL-IRCCS Reggio Emilia
-
Kontakt:
- Francesco Caputo, MD
-
-
RN
-
Rimini, RN, Italien
- Rekruttering
- Oncologia, Ospedale di Rimini
-
Kontakt:
- Francesca Fabbri, MD
-
-
VA
-
Varese, VA, Italien
- Ikke rekrutterer endnu
- Oncologia, ASST SETTE LAGHI, Ospedale di Circolo
-
Kontakt:
- Michele Ghidini, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients will be selected and recruited during routine medical appointments by specialized medical oncologists at the participating cancer center. Patients will be enrolled consecutively based on inclusion and exclusion criteria
Beskrivelse
Inclusion Criteria:
- Provide a signed and dated informed consent form (ICF)
- Willing to comply with all study procedures and be available for the duration of the study
- Male or female, aged 18-49 years old at time of EoGI cancer diagnosis
- Patients with newly diagnosed early-onset gastrointestinal cancer histologically confirmed: colorectal, gastroesophageal and pancreatic tumor site, regardless of histological type
- Any disease stage, performance status, and type of treatment, including experimental therapies and supportive care
- Previous or concomitant malignancies are allowed provided they do not involve the gastrointestinal tract
Exclusion Criteria:
- Cognitive, linguistic, or physical barriers that prevent a detailed reconstruction of the patient's personal medical history including past lifestyle habits
- Having previously received any treatments directed at the newly diagnosed EOGI cancer (i.e., at the time of inclusion, the patient has not yet started any type of treatment, excluding surgery)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
EoGI-kræftpatienter nydiagnosticerede
|
to characterize the distinctive features of EO-GI cancer through a comprehensive approach that considers clinical and demographic factors, tumor features, and patient lifestyle habits, in a real-world Italian settings, mainly located in Northern Italy |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary outcome
Tidsramme: One year from the enrollment
|
Describe clinical and tumor features of newly diagnosed EoGI cancer patients in a real-world Italian setting. |
One year from the enrollment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Secondary outcome measure
Tidsramme: Six and twelve months follow-up
|
EoGI cancer type of treatment at diagnosis (chemotherapy, immunotherapy, targeted therapy, surgery, radiotherapy or best supportive care); progression of disease (if any) and survival status at 6 and 12 months follow-up. |
Six and twelve months follow-up
|
|
Secondary Outcome
Tidsramme: Two years
|
Incidence and prevalence of newly diagnosed EoGI cancer at each participating site during the study accrual time period |
Two years
|
|
Secondary Outcome
Tidsramme: One years from enrollment
|
Description of patients' lifetime exposure to behavioral and cancer-related risk factors |
One years from enrollment
|
|
Secondary Outcome
Tidsramme: One years from enrollment
|
Identify associations between past lifestyle habits (diet, physical activity, smoking, alcohol consumption,) and tumor-related features (stage, histology, anatomical site, and molecular markers) in EoGI cancer patients |
One years from enrollment
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- GOIRC-03-2025
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .